用于肠-大脑相互作用障碍的处方止痛药:比较使用模式与临床实践建议
1Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Neurogastroenterology and motility
|July 5, 2023
概括
在肠-大脑相互作用 (DGBI) 障碍中治疗胃肠道疼痛是具有挑战性的. 这项研究审查了全球DGBI患者处方止痛药和治疗使用情况.
科学领域:
- 胃肠病学和神经胃肠病学
- 疼痛管理 疼痛管理
- 肠-大脑相互作用的障碍 (DGBI)
背景情况:
- 胃肠道疼痛是管理肠-大脑相互作用 (DGBI) 障碍的主要挑战.
- 目前的治疗方案包括药理学药物和行为疗法,用于疼痛主导的DGBI,如刺激性肠综合征和功能性消化不良.
- 有效的疼痛管理策略对于改善患者的生活质量至关重要.
研究的目的:
- 检查DGBI患者处方止痛药使用的全球模式.
- 为提供对DGBI疼痛的药理和非药理治疗使用的概述.
- 在临床实践建议中对这些使用模式进行上下文化.
主要方法:
- 罗马基金会全球流行病学研究数据的回顾性分析.
- 对处方止痛药类别的审查:阿片类药物,中央神经调节剂,抗药和外周作用药物.
- 包括非药物疗法和临床实践指南.
主要成果:
- 罗等人. 在此之前. 研究了来自罗马基金会的全球DGBI患者数据.
- 该研究分析了各种疼痛管理剂和非药物治疗的使用情况.
- 结果提供了对DGBI疼痛的当前临床实践的见解.
结论:
- 了解全球DGBI疼痛管理趋势至关重要.
- 综述强调了利用各种治疗方法.
- 这项研究为临床实践和未来的DGBI疼痛管理策略提供了信息.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
217
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
217
Analgesia and Pain Management
665
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
665
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
314
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
314
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
248
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
248
Drugs for Treatment of Constipation-Predominant IBS
225
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
225
Irritable Bowel Syndrome III: Medical and Nursing Management
245
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
245


